ESI Virtual Prototyping Supports JMDA’s Red Dot Award
22.10.2020 10:00:00 EEST | Business Wire | Press release
With a relationship that spans more than a decade, JMDA Design and ESI Group (Paris:ESI) worked together on the Tinyseats child car seat project which resulted in the highly acclaimed Red Dot Award: Design Concept 2020.
Multi-award winning JMDA Design has collaborated with ESI Group, a global player in virtual prototyping software and services for industrials, for many years. Their unique partnership enabled the Tinyseats child car seat project from Tinyseats Europe AB to undergo rigorous testing without the need of any physical prototypes. They were able to do this at the early stages of development to gain additional information about product performance and to help de-risk compliance challenges in a test situation. Using Virtual Prototyping by working with ESI Group, particularly for innovative, cutting-edge child restraint systems (CRS), ensures dynamic performance is optimised with controlled time and investment, from the upstream phases of the product design process.
Derrick Barker, Founder and Director at JMDA explains, “The Red Dot Award: Design Concept 2020 for the Tinyseats child car seat was a ground-breaking project aiming to achieve a very lightweight, compact and convertible car seat for children from 9 months old. Working with ESI Group enabled JMDA to gain substantial insight into the performance of the car seat early on in the design process, especially the load bearing structure, which could be fully evaluated in a virtual environment.” Derrick adds, “As our relationship goes from strength to strength with ESI Group we are backed by a team sharing our passion for innovation with the highest safety standards”.
“We are really proud to be part of JMDA journey for many years now. Their commitment toward safety and comfort compelled with their undisputed design expertise make them a key player in the car seat industry. Helping industrials to commit to such outcome is truly embarked in our DNA and our strategy. This Red Do Award proves that allowing any compromise between, design, safety and performance is possible with the appropriate expertise, solutions and trust-based relationship.” declares Jonas Fredriksson, Managing Director – ESI Northern Europe
JMDA Design, a global provider for product design services with nearly 30 years’ experience in the industry, is currently designing their 105th child car seat, have. Partnering with world leading specialists, like ESI Group, is a critical part of ensuring a truly holistic approach to innovative product design.
About ESI
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.
Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
For more information about the partnership between JMDA Design and ESI Group, please give Derrick Barker a call on +44 (0) 1386 426100 or email derrick.barker@jmda.co.uk.
- ENDS -
Notes to Editor
- JMDA Design specialise in the design and development of a diverse range of products including child car seats, stair lifts, showers, smoke alarms and highchairs.
- JMDA Design have two offices one in Pershore, Worcestershire and one in Shanghai, China.
- They support clients across the world with testing, manufacturing and distribution of the products they design.
- Awards for innovation and international activity include:
2020 – Winners of Red Dot Award: Design Concept 2020
2019 - Winners of The Queen’s Awards for Enterprise: International Trade 2019
2019 – Winners of a German Design Award 2020
2018 – International Design Award Winners
2017 - Highly Commended ‘Exporter of the Year’ - Hereford and Worcestershire Chamber of Commerce Awards
2016 – Winners of Red Dot Award: Design Concept 2016
2014 – Winner of the Progressive Preschool Innovation Award (Flippa Folding Dining Booster)
2012 – Finalist of the Hereford and Worcestershire Chamber of Commerce International Business Award
2010 – Winner of the International Business of the Year Award
2009 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Kind & Jugend Innovation Award
2008 – Finalist of the Chamber of Commerce Small Business of the Year Award
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005088/en/
Contact information
ESI – Press contact
Florence Barré
press@esi-group.com
SHAN – Press Relations
Esigroup@shan.fr
For more information contact:
Christina Darling – Marketing & PR Manager
JMDA
Units 1 Common Barns
Hill Furze, Nr Pershore
Worcestershire
WR10 2NU
Phone: +44 (0) 1386 426100
Mobile: +44 (0) 7719 430267
Fax: +44 (0) 01386 426048
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
